Table 1.
Clinicopathological characteristics of the studied groups.
| Characteristics | Serum Samples | p-Value a | Tissue Samples | p-Value a | ||||
|---|---|---|---|---|---|---|---|---|
| All | BPH | PCa | All | NT | PCa | |||
| n = 102 | n = 62 | n = 40 | n = 54 | n = 28 | n = 26 | |||
| AGE | ||||||||
| average | 67.98 | 67.93 | 68.02 | 0.482 | 66.90 | 67.88 | 65.92 | 0.716 |
| range | 48–85 | 58–85 | 48–78 | 48–79 | 48–79 | 48–79 | ||
|
PSA
(ng/mL) |
||||||||
| average | 10.99 | 7.10 | 14.88 | 0.0001 | 12.29 | 14.47 | 20.11 | 0.111 |
| range | 2.7–108 | 2.7–20 | 3.8–108 | 3.43–108 | 3.43–52.6 | 4.1–108 | ||
| 2.5–4.0 | 6 | 5 | 1 | 2 | 2 | 0 | ||
| 4.01–10.0 | 73 | 50 | 23 | 29 | 15 | 14 | ||
| 10.01–20.0 | 16 | 7 | 9 | 6 | 3 | 3 | ||
| >20.0 | 7 | 0 | 7 | 17 | 8 | 9 | ||
| GS 6 | 20 (50%) | 11 (42.3%) | ||||||
| GS 7 | 9 (22.5%) | 7 (26.9%) | ||||||
| GS 8 | 5 (12.5%) | 3 (11.5%) | ||||||
| GS 9 | 6 (15%) | 5 (19.2%) | ||||||
|
EAU
Group Risk |
||||||||
| Low-risk | 15 (37.5%) | 13 (50%) | ||||||
| Intermediate-risk | 11 (27.5%) | 4 (15.4%) | ||||||
| High-risk | 14 (35%) | 9 (34.6%) | ||||||
Abbreviations: NT, normal (non-cancerous) tissue; BPH, benign prostatic hyperplasia patients; GS, Gleason score; PSA, prostate specific antigen; EAU, European Association of Urology; a p-values (Mann-Whitney U test) indicate significance of the difference between cohorts with and without diagnosed PCa for the clinicopathological variables.